spacer
home > ebr > winter 2002 > non-viral gene delivery methods
PUBLICATIONS
European Biopharmaceutical Review

Non-Viral Gene Delivery Methods

The last decade has seen substantial progress in the development and application of non-viral vectors in gene therapy. Infectious disease, genetic defects and even traumatic injury may someday be treated with gene therapy and gene transfer strategies. The potential impact of this new technology on human disease has produced optimism and expectation for scientists and lay people alike. As more effort is directed at developing the potential of this technology, it has become evident that the success or failure of gene therapeutic approaches will centre on the ability to manipulate and control the process of genetic transfer into somatic cells.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Günter Kraus, Vice President of Research and Development at amaxa GmbH Dr Günter Kraus is Vice President of Research and Development at amaxa GmbH, a German biotechnology company based in Cologne. Prior to joining the company in 2002, he spent 12 years at two academic institutions in the USA, where he was a Principal Investigator into DNA-based HIV vaccines, and received a prestigious amfAR award and a Susan G. Komen Foundation breast cancer research award. Günter holds a PhD in Microbiology from the JohannWolfgang-Goethe University, Germany and wrote his thesis on infectious diseases at the Paul-Ehrlich Institute.
He has extensive knowledge of the development of viral and non-viral gene delivery systems and in the field of gene therapy. He has also co-authored numerous research articles in peer reviewed scientific journals and several US-issued patents.

spacer
Dr Günter Kraus
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI expert forecasts ‘huge growth in Middle East manufacturing with Europe a medium-term target’

CPhI Middle East & Africa (CPhI MEA) expert Madhukar Tanna, Chief Executive Officer of Pharmax, a United Arab Emirates (UAE) based branded generic manufacturer, says favourable conditions in the UAE are resulting in a boom of pharmaceutical manufacturing throughout the region. Government incentive schemes to increase domestic production, coupled with a brand friendly environment and rising healthcare needs is fuelling surging demand – with many new companies and plants launching in the last two years alone.
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement